Sign In
Buy PRME
$3.14
-0.0700 (-2.18%)
At Close: Jun 03, 2026
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
08:00am, Wednesday, 03'rd Jun 2026
CAMBRIDGE, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapi
Prime Medicine to Present at Jefferies Global Healthcare Conference
08:00am, Thursday, 28'th May 2026
CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
12:16pm, Thursday, 07'th May 2026
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.4 per share a year ago.
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
08:00am, Thursday, 07'th May 2026
CAMBRIDGE, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapie
Prime Medicine Appoints Svetlana Makhni as Chief Financial Officer
08:00am, Thursday, 16'th Apr 2026
CAMBRIDGE, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therap
Prime Drink Group Announces Convertible Debenture, Board Appointment and Grant of Differed Share Units
08:28pm, Tuesday, 14'th Apr 2026
MONTRÉAL, April 14, 2026 (GLOBE NEWSWIRE) -- Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) announces a non-brokered private placement (the “Private Placement”) of a minim
Contrasting Athira Pharma (NASDAQ:LONA) & Prime Medicine (NASDAQ:PRME)
02:46am, Wednesday, 25'th Mar 2026
Prime Medicine (NASDAQ: PRME - Get Free Report) and Athira Pharma (NASDAQ: LONA - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the
Financial Analysis: Prime Medicine (NASDAQ:PRME) & Athira Pharma (NASDAQ:LONA)
01:10am, Wednesday, 25'th Mar 2026
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will contrast the
Head to Head Review: AgomAb Therapeutics (NASDAQ:AGMB) vs. Prime Medicine (NASDAQ:PRME)
01:17am, Friday, 20'th Mar 2026
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the superior stock? We will contrast t
Prime Medicine (NASDAQ:PRME) and Athira Pharma (NASDAQ:LONA) Head to Head Review
02:14am, Thursday, 19'th Mar 2026
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will compare the two
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
02:08am, Monday, 16'th Mar 2026
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast
Athira Pharma (NASDAQ:LONA) vs. Prime Medicine (NASDAQ:PRME) Financial Analysis
02:23am, Monday, 09'th Mar 2026
Athira Pharma (NASDAQ: LONA - Get Free Report) and Prime Medicine (NASDAQ: PRME - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the tw
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
05:25pm, Friday, 06'th Mar 2026
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of “Moderate Buy” from Analysts
04:00am, Friday, 06'th Mar 2026
Prime Medicine, Inc. (NYSE: PRME - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the stock, MarketBeat Ratings reports.
182,133 Shares in Prime Medicine, Inc. $PRME Acquired by DNB Asset Management AS
04:19am, Wednesday, 04'th Mar 2026
DNB Asset Management AS purchased a new stake in Prime Medicine, Inc. (NYSE: PRME) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
